NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02115204,"4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF",https://clinicaltrials.gov/study/NCT02115204,,COMPLETED,"Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer (BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear. West German Study Group and ""Arbeitsgemeinschaft Gyn√§kologische Onkologie"" (WSG-AGO) EC-Doc is a large trial evaluating modern sequential taxane-based chemotherapy in the subgroup with 1-3 involved lymph nodes (LN).",NO,Breast Cancer,DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Methotrexate|DRUG: 5-fluorouracil,"Comparison of event-free survival, 60 months after end of treatment","Comparison of overall survival, 60 months after end of treatment|Comparison of toxicity (measured as number of adverse events), 60 months after end of treatment|Comparison of quality of life, 60 months after end of treatment|Comparison of cost effectiveness across the applied regimens in relation to event-free survival, 60 months after end of treatment",,West German Study Group,AGO Germany,FEMALE,"ADULT, OLDER_ADULT",PHASE3,2011,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,EC-Doc,2000-06,2005-08,2010-08,2014-04-15,,2019-10-03,"Ev. Hospital Bethesda, Moenchengladbach, 41061, Germany",
